Erectile Dysfunction (Procedures)
For pathophysiology, evaluation, and natural history, see Erectile Dysfunction in Clinical Conditions. For implant-specific operative deep-dives, see the Penile Implants subsection.
Decision Framework
ED management is patient-centered and shared-decision based. The AUA 2018 Erectile Dysfunction Guideline asks clinicians to inform every man of all treatment options that are not medically contraindicated, and holds that beginning with any option is valid regardless of invasiveness or reversibility; the EAU 2025 Male Sexual & Reproductive Health Update, carried into the March 2026 limited update, likewise replaces the traditional three-tier concept with a personalized algorithm.[1][2][18] The EAU 2026 recommendations rate PDE5 inhibitors first-line , intracavernosal injection an alternative first-line or second-line option , topical or intraurethral alprostadil, vacuum devices and low-intensity shockwave weak, and prosthesis for failure of other treatment or by preference .[18] In practice most men move from least to most invasive, with selection guided by severity, etiology, comorbidities, and patient/partner preference; the ladder below reflects that usual sequence. The EAU 2025 update emphasizes personalized treatment: patients should be fully counseled on every available modality and choose based on invasiveness, tolerability, effectiveness, and personal expectations.[2] The AUA 2018 guideline advises against penile venous surgery for men with ED , and EAU 2026 no longer recommends venous ligation for veno-occlusive dysfunction because of poor long-term results.[1][18] Combination therapy (PDE5i plus a second agent or device) improves IIEF modestly over monotherapy (mean +1.8 points; larger in monotherapy-resistant and post-prostatectomy ED) and may be considered for refractory, complex, or difficult-to-treat ED; most individual add-ons rest on single studies and heterogeneity is high.[4] In one 40-patient observational cohort, successful immediate salvage was associated with a mean 0.6 cm reduction in total corporeal length versus 3.7 cm after delayed reimplantation.[14][15]
Treatment Selection by Clinical Scenario
| Clinical Scenario | First-Line | Alternative(s) | Avoid |
|---|---|---|---|
| Newly diagnosed ED, no contraindications | Lifestyle modification + PDE5 inhibitor, with correct-use instruction, repeated attempts as needed, and dose titration to optimal efficacy and tolerability[1][18] | Daily tadalafil 5 mg for concurrent BPH/LUTS; for ED alone or preference for spontaneity, 2.5 mg once daily may be increased to 5 mg based on response and tolerability[21] | Skipping cardiovascular risk assessment; declaring failure before reviewing correct use and titrating the dose as tolerated |
| Symptomatic hypogonadism confirmed by two low morning fasting total-testosterone measurements + ED[18] | Testosterone replacement, after assessing fertility intent, for mild hypogonadal ED ; PDE5i plus testosterone for more severe hypogonadal ED [18] | PDE5i alone (AUA: may work better combined with testosterone when deficiency is confirmed, defined as total T <300 ng/dL plus symptoms/signs) | Testosterone alone without confirmed hypogonadism, or as sole treatment for moderate/severe hypogonadal ED (AUA advises against testosterone as ED monotherapy; EAU recommends it first-line for mild hypogonadal ED, strong)[1][18] |
| PDE5i non-responder after an adequately instructed, individually titrated trial[18] | If a patient prefers another PDE5i trial after discussing ICI, VED alone and prosthesis, consider switching agents, daily tadalafil, PDE5i plus VED, or PDE5i plus intraurethral alprostadil where available[18][26] | Intracavernosal injection (ICI) | Prosthesis implantation without counseling on benefits, harms and other suitable options[1][18] |
| PDE5i failure / intolerance, prefers pharmacotherapy | ICI (alprostadil or a compounded combination selected by response and tolerability), with an in-office injection test and technique training followed by instructed home dose titration[1][18] | Intraurethral alprostadil where available (MUSE is discontinued in the US) | Self-titration without supervised first dose (priapism risk) |
| Prefers non-pharmacologic option | Vacuum erection device | Psychosexual therapy when indicated (EAU: CBT with a partner alongside treatment, strong)[18] | Restrictive ring >30 minutes (ischemia/skin-necrosis risk); VED use with bleeding disorders or anticoagulant therapy (EAU contraindications)[18] |
| Concurrent nitrate use (any formulation) | VED, ICI (alprostadil monotherapy) | MUSE | All PDE5 inhibitors (absolute contraindication)[18] |
| Post-radical prostatectomy ED (early after surgery) | Offer PDE5i, VED or ICI early for assisted erections after prostatectomy ; VED may preserve penile size, but faster spontaneous erectile recovery has not been demonstrated[18][27] | Daily tadalafil | Promising unassisted recovery from early PDE5i (AUA: may not improve spontaneous, unassisted function)[1] |
| Mild–moderate vasculogenic ED, partial PDE5i response, prefers regenerative adjunct | Consider Li-ESWT with or without PDE5i after counseling on uncertain clinical benefit [5][1][18] | Intracavernous PRP only in a clinical trial (EAU 2026; AUA experimental)[18][1] | Stem-cell therapy (AUA: investigational)[1] |
| Refractory to optimized conservative + medical therapy, or patient preference | 3-piece IPP (AMS 700 series or Coloplast Titan) | 3-piece IPP with an ectopic reservoir when feasible after prior pelvic surgery; 2-piece IPP if safe reservoir placement is not feasible[18]; malleable (limited dexterity, neophallus, salvage, cost-constrained) | Continued failed pharmacotherapy without device counseling |
| Peyronie's disease + ED unresponsive to medical therapy | IPP with or without adjunctive straightening; assess curvature after cylinder insertion. For residual curvature <30°, no further maneuver is indicated; for >30°, Wilson manual modeling may be proposed, followed by tunical plication or plaque incision/grafting if >30° persists.[24] | (See Peyronie's algorithm) | Routine straightening for residual curvature <30° |
| Severe corporal fibrosis (post-priapism, post-explant) | Malleable prosthesis at high-volume center | Staged dilation → 3-piece IPP | Standard 3-piece in densely fibrosed corpora without dilation strategy |
| Acute prosthesis infection | Assess medical stability and local tissue viability; discuss immediate complete explantation, washout and reimplantation (IPP or malleable) with suitable patients[10][18] | Extracapsular reimplantation (mature capsule) | Treating delayed reimplantation as categorically inferior; EAU 2026 makes no general recommendation after explantation. In a selected 40-patient cohort, mean measured total corporeal length loss was 3.7 cm after delayed reimplantation versus 0.6 cm after successful immediate salvage; discuss infection control, tissue viability and patient goals.[15][18] |
| Young man with traumatic arterial injury (no atherosclerosis) | Penile arterial revascularization at high-volume center (IEA → dorsal penile artery, Michal II); AUA: conditional recommendation for young men with focal arterial occlusion and no generalized vascular disease or veno-occlusive dysfunction, with long-term success not well established[1] | ICI / PDE5i bridge during workup | Revascularization for atherosclerotic ED (poor outcomes) |
Timing of rehabilitation after prostatectomy has been compared in one nonrandomized cohort. Among men with fully functional preoperative erections who had bilateral nerve-sparing radical prostatectomy and committed to pharmacological rehabilitation (sildenafil, then intracavernosal injection if needed), 48 who started before 6 months (mean 2 months) had a higher IIEF erectile-function domain score at 2 years than 36 who started at 6 months or later (mean 7 months; 22 vs 16, p < 0.001), with more unassisted (58% vs 30%) and sildenafil-assisted (86% vs 45%) functional erections. The groups were matched for age, comorbidity and baseline erectile function, but treatment timing was not randomized.[19]
Stepwise Treatment Ladder
| Step | Tier | Expected Efficacy | When to Advance |
|---|---|---|---|
| 0 | Lifestyle modification + risk-factor optimization (weight loss, exercise, smoking cessation, medication review, treat hypogonadism) | Small average improvement; individual lifestyle trials in the AUA review report IIEF gains of roughly 1–4 points, larger in a subset of men[1] | Insufficient response, or patient desires faster improvement |
| 1 | PDE5 inhibitor monotherapy at maximum tolerated dose | Effective across IIEF and sexual-encounter outcomes; no single pooled successful-intercourse rate reported[3] | Failure after dose titration + counseling |
| 1B | Combination therapy — PDE5i + testosterone (if hypogonadal), PDE5i + VED, agent switch, daily tadalafil | Mean IIEF +1.8 over monotherapy in a JAMA Netw Open meta-analysis of 44 studies (3,853 men); add-on VED, Li-ESWT and daily tadalafil each rest on single studies[4] | Failure of an optimized combination, intolerance, or informed preference for another option, including prosthesis after counseling on benefits and harms[18] |
| 2A | Intracavernosal injection (alprostadil, bimix, or trimix) | Intracavernosal alprostadil has efficacy rates above 70% in the general ED population and in subgroups such as men with diabetes or cardiovascular disease[3][18]; in one 32-man randomized injection comparison restricted to high-dose bimix nonresponders, trimix induced erections permitting penetration in 16/32 (50%) versus 7/32 (22%) with alprostadil alone[3][25]. EAU 2026 cites TriMix efficacy reaching 92%[18]; in a 1,412-man tertiary injection program, 89% of TriMix users could have intercourse[29], and after bilateral nerve-sparing robotic prostatectomy, stepwise TriMix escalation gave erections satisfactory for intercourse in 29/34 (85%) PDE5i-refractory men[30]. A 2025 meta-analysis found no consistent adverse-effect advantage for combined over single-agent injections[8] | Failure, intolerance, dropout (41–68% reported)[18], or patient preference for definitive solution |
| 2B | Intraurethral alprostadil (MUSE) or vacuum erection device | MUSE: among 1,511 men with primarily organic ED tested in clinic, 996 responded; of 961 home-treatment reporters, intercourse occurred at least once within three months in 299/461 (64.9%) assigned alprostadil versus 93/500 (18.6%) assigned placebo.[3][22] In a second trial, 159/249 men passed office testing; 69% assigned alprostadil versus 11% assigned placebo reported intercourse at least once during three months.[23]; VED: published efficacy for erections satisfactory for intercourse was as high as 90%[18] | Insufficient response or dissatisfaction |
| 2.5 | Regenerative therapy — Li-ESWT (best evidence), PRP (experimental; only in IRB-approved clinical research)[1][18] | Li-ESWT mean IIEF +2.0 (95% CI 0.99–3.00) in a 2017 meta-analysis of 14 studies[6]; the 2025 Cochrane review (21 sham-controlled RCTs) found a short-term IIEF-EF gain of about 3.9 points, below the 4-point minimal important difference, with low-certainty evidence and no adverse-event signal[5]. AUA 2018 classes Li-ESWT as investigational , stem-cell therapy as investigational and PRP as experimental[1][7] | Insufficient response → Step 3 |
| 3 | Penile prosthesis implantation (3-piece IPP preferred) | An ICSM-cited AMS 700 CX series reported 97% patient and 92% partner satisfaction; EAU 2026 cites 92–100% of patients and 91–95% of partners across prosthesis implantation[9][10][18] | Definitive endpoint; irreversible |
MUSE remains a guideline option, but FDA now lists every MUSE strength as discontinued in the United States; see intraurethral alprostadil before planning it.
IPP Device-Selection Sub-Comparison
| Feature | 3-Piece IPP | 2-Piece IPP | Malleable (Semi-Rigid) |
|---|---|---|---|
| Components | Two cylinders + scrotal pump + retropubic (or ectopic) reservoir | Two corporal cylinders + scrotal pump; fluid storage varies by model (see implant models)[9][10] | Two bendable rods |
| Naturalness | Most natural erection / flaccidity; described as the gold standard in advanced-economy countries[9] | Intermediate rigidity; limited fluid volume | Always semi-rigid — concealment difficult |
| Mechanical survival | Five-year mechanical survival varied by three-piece model in ICSM-cited series (AMS 700 CX 85%, Ultrex 74%, Mentor Alpha-1 90%, Alpha NB 94%)[10][11]; EAU 2026 cites <5% failure at five years for modified three-piece models, while pooled implant survival across models was 87.2% at five years and 76.8% at ten years[18] | Limited Ambicor data: 94–100% mechanical survival in three older series (mean follow-up 29–43 months)[10] | Highest — no hydraulic components |
| Surgical complexity | Most complex (reservoir placement) | Avoids retropubic reservoir | Simplest |
| Cost | Highest | Intermediate | Lowest |
| Ideal candidate | Standard candidate with adequate dexterity, no reservoir contraindication | Prior pelvic / abdominal surgery making reservoir placement risky | Limited dexterity; neophallus; cost constraints; salvage after infection |
Prosthesis Infection Salvage — Length-Preservation Hierarchy
| Strategy | Technique | Infection-Free Rate | Length Impact |
|---|---|---|---|
| Immediate IPP salvage (Mulcahy) | Historical Mulcahy seven-solution washout after complete explantation, followed by same-session IPP reimplantation; contemporary irrigants and sequences vary[14][12] | 45/55 (82%) infection-free among 65 enrolled (10 without known outcome); follow-up 6–93 months[28] | Successful immediate salvage cohort (not IPP-specific): mean 0.6 cm total corporeal length loss[15] |
| Immediate malleable salvage | Mulcahy washout + malleable prosthesis; 17/54 infection-free patients (31%) later underwent conversion to IPP at a mean of 6.7 mo[13] | 93% multi-institution (54/58); 70.5% infection-free overall in 76 VA salvage patients (61 malleable, 15 IPP); malleable-specific rate not reported (reinfection 45.5% with diabetes versus 20.5% without)[16] | Preserves length |
| Extracapsular salvage | Explant infected or eroded device, wash capsule, reimplant in extracapsular sinusoidal space[17] | 94.4% infection-free (17/18 with a developable plane, from 20 cases; follow-up 7–38 months) | Bypasses contaminated capsule |
| Delayed reimplantation | Explant, then reimplant after infection resolution; a 3–6-month delay has been described[20] | Standard | Mean 3.7 cm corporeal length loss in the delayed-reimplantation cohort, irreversible[15] |
In a 40-patient observational cohort, successful immediate salvage was associated with a mean 0.6 cm reduction in measured total corporeal length versus 3.7 cm after delayed reimplantation.[15] In medically suitable patients, discuss immediate salvage and its alternatives.[15][18] For coating-specific irrigation evidence, see the implant-infection article.
Treatment Database
| Treatment | Tier | Invasiveness | Best for / indication |
|---|---|---|---|
| Lifestyle Modification | Lifestyle / Behavioral | Non-invasive | Universal first step — exercise, weight, sleep, smoking cessation. |
| Psychosexual Therapy | Lifestyle / Behavioral | Non-invasive | Predominantly psychogenic ED or performance anxiety. |
| PDE5 Inhibitors | Oral Pharmacotherapy | Non-invasive | First-line pharmacotherapy across most etiologies. |
| Testosterone Replacement Therapy | Oral Pharmacotherapy | Non-invasive | Symptomatic hypogonadism with low testosterone on repeat morning labs. |
| Vacuum Erection Device (VED) | Mechanical | Non-invasive | PDE5-failure or post-prostatectomy rehab. |
| Intraurethral Alprostadil (MUSE) | Intraurethral | Minimally Invasive | PDE5-failure when patient declines injection. |
| Intracavernosal Injection | Injectable | Minimally Invasive | Reliable on-demand second-line therapy after PDE5 failure. |
| Low-Intensity Shockwave Therapy (Li-ESWT) | Regenerative / Emerging | Non-invasive | Mild-to-moderate vasculogenic ED; investigational. |
| Platelet-Rich Plasma (PRP) | Regenerative / Emerging | Minimally Invasive | Investigational regenerative adjunct; counsel on limited evidence. |
| Stem Cell Therapy | Regenerative / Emerging | Minimally Invasive | Investigational — trial settings only. |
| Penile Implant | Surgical Prosthesis | Surgical Implant | Definitive therapy after non-surgical options fail or are declined. |
| Penile Arterial Revascularization | Vascular Surgery | Surgical Open | Young patients with isolated post-traumatic arteriogenic ED. |
| Venous Ligation Surgery (± Embolization) | Vascular Surgery | Surgical Open | Not recommended for ED by the AUA 2018 guideline <Rec>(Moderate, Grade C)</Rec> or EAU 2026 because of poor long-term results. |
See Also
- Erectile Dysfunction (Clinical Conditions). Pathophysiology, evaluation, full clinical workup
- Penile Implants subsection
- Peyronie's Disease — operative decision support
- Pharmacology — Sexual Medicine & Andrology
- On WHITWIKI, the sister site for GU oncology: Sexual Function and Fertility, Nerve-Sparing Prostatectomy.
References
1. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004
2. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. Eur Urol. 2025;88(1):76–102. doi:10.1016/j.eururo.2025.04.010
3. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–488. doi:10.1016/j.jsxm.2016.01.016
4. Mykoniatis I, Pyrgidis N, Sokolakis I, et al. Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(2):e2036337. doi:10.1001/jamanetworkopen.2020.36337
5. Ergun O, Kim K, Kim MH, et al. Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2025;7:CD013166. doi:10.1002/14651858.CD013166.pub3
6. Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71(2):223–233. doi:10.1016/j.eururo.2016.05.050
7. Capogrosso P, Albersen M, Burnett AL, et al. Erectile dysfunction: update on clinical management. Eur Urol. 2025;88(4):388–399. doi:10.1016/j.eururo.2025.05.004
8. Lima AS, Villela BC, Pustilnik HN, et al. Comparison of adverse effects of combined and isolated substances in intracavernosal injection: a systematic review and meta-analysis. J Sex Med. 2025:qdaf172. doi:10.1093/jsxmed/qdaf172
9. Goodstein T, Jenkins LC. A narrative review on malleable and inflatable penile implants: choosing the right implant for the right patient. Int J Impot Res. 2023;35(7):623–628. doi:10.1038/s41443-023-00765-7
10. Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: current recommendations from the International Consultation on Sexual Medicine. J Sex Med. 2016;13(4):489–518. doi:10.1016/j.jsxm.2016.01.017
11. Ancha N, Eldin M, Woodle T, et al. Current devices, outcomes, and pain management considerations in penile implant surgery: an updated review of the literature. Asian J Androl. 2024;26(4):335–343. doi:10.4103/aja202386
12. Mahdi M, Campos LR, Yafi FA. Immediate salvage procedure for infected penile prostheses: a review of the advances in surgical technique and antimicrobial strategies. Int J Impot Res. 2025. doi:10.1038/s41443-025-01133-3
13. Gross MS, Phillips EA, Balen A, et al. The malleable implant salvage technique: infection outcomes after Mulcahy salvage procedure and replacement of infected inflatable penile prosthesis with malleable prosthesis. J Urol. 2016;195(3):694–697. doi:10.1016/j.juro.2015.08.091
14. Swanton AR, Gross MS, Munarriz RM, Mulcahy JJ. Penile prosthesis salvage: a historical look at the Mulcahy technique and a review of the latest literature. Int J Impot Res. 2023;35(2):90–94. doi:10.1038/s41443-021-00515-7
15. Lopategui DM, Balise RR, Bouzoubaa LA, Wilson SK, Kava BR. The impact of immediate salvage surgery on corporeal length preservation in patients presenting with penile implant infections. J Urol. 2018;200(1):171–177. doi:10.1016/j.juro.2018.01.082
16. Angulo-Llanos L, Sandler MD, Howell NB, Williams A, Masterson III TA. Outcomes of salvage procedures with malleable implants for penile prosthesis infections in the Veterans Affairs national medical system: a real-world, multi-surgeon retrospective analysis over a decade. J Sex Med. 2026;23(3):qdag042. doi:10.1093/jsxmed/qdag042
17. Shaeer O, Shaeer K, Soliman AbdelRahman IF. Salvage and extracapsular implantation for penile prosthesis infection or extrusion. J Sex Med. 2019;16(5):755–759. doi:10.1016/j.jsxm.2019.02.005
18. EAU. Guidelines on Sexual and Reproductive Health, Limited Update March 2026, sections 5.6, 5.6.11 and 5.6.12.
19. Mulhall JP, Parker M, Waters BW, Flanigan R. "The Timing of Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy Affects the Recovery of Erectile Function." BJU Int. 2010;105(1):37-41. doi:10.1111/j.1464-410X.2009.08775.x
20. Cayetano-Alcaraz AA, Yassin M, Desai A, et al. "Penile implant surgery—managing complications." Fac Rev. 2021;10:73. doi:10.12703/r/10-73
21. Bostal LLC. Tadalafil tablets, US prescribing information. Updated February 4, 2026. Sections 2.2–2.4. DailyMed.
22. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. "Treatment of men with erectile dysfunction with transurethral alprostadil." N Engl J Med. 1997;336(1):1–7. doi:10.1056/NEJM199701023360101
23. Williams G, Abbou CC, Amar ET, et al. "Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction." Br J Urol. 1998;81(6):889–894. doi:10.1046/j.1464-410x.1998.00703.x
24. European Association of Urology. "EAU Guidelines on Sexual and Reproductive Health: Penile Curvature." 2026. Official guideline.
25. Bechara A, Casabé A, Chéliz G, Romano S, Fredotovich N. "Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses." J Urol. 1996;155(3):913–914. PMID 8583605. doi:10.1016/s0022-5347(01)66344-4
26. Stern N, Bajic P, Campbell J, et al. "Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)." Sex Med Rev. 2025;13(4):513–537. doi:10.1093/sxmrev/qeaf035
27. Wang R, Martins FE, Ralph D, et al. "Vacuum erectile devices for erectile dysfunction: recommendations from the 5th international consultation on sexual medicine." Sex Med Rev. 2025;13(2):172–183. doi:10.1093/sxmrev/qeaf002
28. Mulcahy JJ. "Long-term experience with salvage of infected penile implants." J Urol. 2000;163(2):481–482. PMID 10647660. doi:10.1016/s0022-5347(05)67906-2
29. Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. "A review of outcomes of an intracavernosal injection therapy programme." BJU Int. 2012;110(11):1787-1791. doi:10.1111/j.1464-410X.2012.11080.x
30. Veredgorn Y, Savin Z, Marom R, Herzberg H, Nevo A, Yossepowitch O, Dekalo S. "Predictors of successful erectile function using intracavernosal injection in post-prostatectomy men with erectile dysfunction." Can Urol Assoc J. 2026;20(5):E170-E175. doi:10.5489/cuaj.9347